Business
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its financial consolidated results for the nine months ended September 30, 2025 and provide a Company update.
About this update from Summit Hotel Properties, Inc.
[{"type":"text","content":"HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its financial consolidated results for the nine months ended September 30, 2025 and provide a Company update.","length":421,"tagName":"p"},{"type":"image","alt":"Innocan Pharma Logo","displaySize":"","headline":null,"caption":"Innocan Pharma Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":283,"url":"https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MQ_objxOFBZ.dAp8fl2HIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ5OTtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166","width":400,"height":283}}},{"type":"text","content":"Iris Bincovich, CEO of Innocan, said: "As published in the esteemed Journal of Precision Nanomedicine and Frontiers in Pharmacology journal, Innocan continues to advance the pre-clinical development of LPT-CBD to support compliance with both the FDA and the CVM requirements for development.","length":296,"tagName":"p"},{"type":"text","content":"Preliminary pharmacokinetic and safety evaluations of LPT-CBD in minipigs, provide encouraging support for Innocan's regulatory strategy to advance LPT-CBD IND-enabling studies in alignment with FDA standards.","length":213,"tagName":"p"},{"type":"text","content":"In addition, meaningful pre-clinical data provides clinically translatable insights supporting the intended chronic use of LPT-CBD for pain management.","length":151,"tagName":"p"},{"type":"text","content":"Despite an unstable US market, the Consumer Wellness business continued to demonstrate resilience and solid profitability, together with continued strengthening of the Company's balance sheet.","length":196,"tagName":"p"},{"type":"text","content":"We are progressing towards the next important milestone of a U.S. public offering.","length":82,"tagName":"p"},{"type":"text","content":"FISCAL 2025 NINE MONTHS SELECT FINANCIAL RESULTS (unaudited)","length":60,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"2","...